94/96 AVENUE LEDRU-ROLLIN

Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease

Retrieved on: 
Tuesday, July 11, 2023
Molecular mimicry, DNA, Circulating tumor DNA, BIRC5, CRC, Liquid biopsy, Cancer, Immunotherapy, Rated R, Trial of the century, MD Anderson Cancer Center, MRD, Service provider, CD8, FOXM1, Patient, Risk, Colorectal cancer, University, Blood, Somatic mutation, Epitope, Neoplasm, UCP2, DFS, Nivolumab, Pharmaceutical industry, Vaccine, Medical imaging

EO2040 is an innovative, off-the-shelf immunotherapy that combines two synthetic OncoMimics™ peptides.

Key Points: 
  • EO2040 is an innovative, off-the-shelf immunotherapy that combines two synthetic OncoMimics™ peptides.
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) FOXM1 & BIRC5.
  • EO2040 also includes universal cancer peptide 2 (UCP2), a helper peptide representing the CD4+ epitope.
  • The CLAUDE study (EOCRC1-22; NCT05350501) is the first trial to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of OncoMimics™ immunotherapy efficacy.

Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer

Retrieved on: 
Friday, June 30, 2023
Molecular mimicry, CDC20, CRC, Microsatellite instability, Non-Hodgkin lymphoma, Immune tolerance, Adrenal tumor, Research, Immunotherapy, Glioblastoma, Assistant, Oncology, Colorectal cancer, Service provider, AP-HP, CD8, FOXM1, Patient, Cancer, Epitope, Neoplasm, Sorbonne University, Nivolumab, Safety, UCP2, Peptide, Inflammation, Vaccine, Pharmaceutical industry, Medical imaging, UBE2C

These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) BIRC5/survivin, FOXM1, UBE2C, CDC20 and KIF2C.

Key Points: 
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) BIRC5/survivin, FOXM1, UBE2C, CDC20 and KIF2C.
  • EO4010 also includes universal cancer peptide 2 (UCP2), a helper peptide representing the CD4+ epitope.
  • The Company is also initiating a Phase 2 clinical study in patients with ctDNA-defined, Minimal Residual Disease of colorectal cancer, with its fourth candidate EO2040.
  • This groundbreaking approach so far demonstrates both efficacy and safety for the patients, instilling real hope in the fight against cancer.”

Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

Retrieved on: 
Wednesday, June 14, 2023
Molecular mimicry, Rituximab, CD20, ICML, Lenalidomide, Lymphoma, CD268, CD22, Adrenal tumor, Immunotherapy, Glioblastoma, Trial of the century, Protein, CD8, Asilomar International Conference on Climate Intervention Technologies, Patient, Standard of care, Colorectal cancer, Epitope, Neoplasm, Poster, Lymphocyte, CD37, Safety, BAFF, UCP2, Conference, Peptide, Inflammation, Vaccine, Pharmaceutical industry

EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides.

Key Points: 
  • EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides.
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37 and CD268 (BAFF receptor).
  • The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL.
  • We are also preparing to enter another new OncoMimics™ candidate, EO4010, for the treatment of metastatic colorectal cancer, into clinical development.”

Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO

Retrieved on: 
Wednesday, May 31, 2023
Maintenance, Bevacizumab, GBM, Vaccination, Nivolumab, Inflammation, Edema, Survival, Cancer, German Cancer Research Center, DSM-IV codes, Glioblastoma, ASCO, Service provider, VEGF, American Society of Clinical Oncology, Patient, Data, Memory, Annual general meeting, Immunosuppression, Society, Pharmaceutical industry, Vaccine, MD

Nivolumab is used as an adjuvant to EO2401, to support T cell expansion and tumor infiltration.

Key Points: 
  • Nivolumab is used as an adjuvant to EO2401, to support T cell expansion and tumor infiltration.
  • By itself, nivolumab has no observed clinical effect on GBM tumors.
  • Pierre Belichard, CEO at Enterome said, “We are thrilled with the clinical and immunological data emerging from the ROSALIE trial, which we are presenting at ASCO.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific CD8+ T cells, correlating with clinical efficacy.

Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors

Retrieved on: 
Tuesday, May 9, 2023

The newly formed SAB and MAG will provide strategic, scientific, and clinical guidance to Enterome as it progresses its pipeline of innovative OncoMimics™ immunotherapies targeting solid and liquid tumors.

Key Points: 
  • The newly formed SAB and MAG will provide strategic, scientific, and clinical guidance to Enterome as it progresses its pipeline of innovative OncoMimics™ immunotherapies targeting solid and liquid tumors.
  • “Their combined knowledge and experience in immune-oncology will be fundamental as we look to advance and expand our pipeline of OncoMimics immunotherapies into and through clinical development targeting solid and liquid cancers.
  • Pedro Romero, MD, PhD is a specialist in translational tumor immunology and immunotherapy of cancer as well as immune and tumoral responses.
  • Pedro’s research which has been published in leading scientific journals has been instrumental to tumor immunology and clinical cancer immunotherapy developments.

Enterome's Management to Attend Upcoming Meetings

Retrieved on: 
Friday, March 10, 2023
Cancer, Inflammation, Spring, Pharmaceutical industry, Cryptocurrency, Clothing

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today announces that its management team will attend and take part in 1-on-1 meetings with potential business partners at the following meetings:

Key Points: 
  • Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today announces that its management team will attend and take part in 1-on-1 meetings with potential business partners at the following meetings:
    BIO-Europe Spring - March 20-22 in Basel, Switzerland
    MATWIN's MEET2WIN - May 11-12 in Bordeaux, France
    Enterome’s CEO, Pierre Belichard, will present an overview of the Company and take part in 1-on-1 meetings with potential investors at the following conferences:
    BioTrinity 2023 - April 25-26 in London, UK
    Bio€quity Europe 2023 - May 14-16 in Dublin, Ireland